Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week High – Still a Buy?

12 Dec 2025, 15:45 by Jessica Moore · The Cerbat Gem

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $71.80 and last traded at $71.8450, with a volume of 676375 shares trading hands. The stock had previously closed at $71.60.

Wall Street Analysts Forecast Growth

RNA has been the subject of several analyst reports. Roth Capital cut shares of Avidity Biosciences from a “strong-buy” rating to a “hold” rating and set a $72.00 price target for the company. in a research report on Monday, October 27th. Bank of America upped their target price on shares of Avidity Biosciences from $56.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Sanford C. Bernstein lowered Avidity Biosciences from an “outperform” rating to a “market perform” rating and raised their price objective for the company from $52.00 to $72.00 in a research report on Monday, October 27th. Wall Street Zen upgraded shares of Avidity Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, October 25th. Finally, Evercore ISI lowered their target price on shares of Avidity Biosciences from $70.00 to $65.00 and set an “outperform” rating on the stock in a research note on Monday, September 22nd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Avidity Biosciences presently has an average rating of “Hold” and a consensus target price of $69.24.

Check Out Our Latest Analysis on RNA

Avidity Biosciences Stock Up 0.3%

The business has a 50-day moving average price of $63.61 and a 200-day moving average price of $46.83. The firm has a market capitalization of $10.83 billion, a price-to-earnings ratio of -17.19 and a beta of 0.90.

Avidity Biosciences (NASDAQ:RNA – Get Free Report) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.22). The company had revenue of $12.48 million during the quarter, compared to analysts’ expectations of $1.80 million. Avidity Biosciences had a negative return on equity of 37.70% and a negative net margin of 2,634.59%.The business’s revenue for the quarter was up 420.8% compared to the same quarter last year. On average, equities research analysts forecast that Avidity Biosciences, Inc. will post -2.89 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Eric Mosbrooker sold 6,562 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $45.38, for a total transaction of $297,783.56. Following the completion of the transaction, the insider directly owned 55,000 shares in the company, valued at $2,495,900. This trade represents a 10.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Steven George Hughes sold 2,209 shares of the company’s stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $47.54, for a total transaction of $105,015.86. Following the sale, the insider owned 38,867 shares in the company, valued at $1,847,737.18. The trade was a 5.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 30,979 shares of company stock valued at $1,495,400. Company insiders own 3.83% of the company’s stock.

Institutional Trading of Avidity Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Avidity Biosciences by 42.9% during the third quarter. Vanguard Group Inc. now owns 13,219,759 shares of the biotechnology company’s stock worth $575,985,000 after acquiring an additional 3,971,457 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Avidity Biosciences by 2.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 11,338,098 shares of the biotechnology company’s stock worth $334,701,000 after purchasing an additional 295,275 shares during the period. Wellington Management Group LLP grew its position in Avidity Biosciences by 8.8% in the 3rd quarter. Wellington Management Group LLP now owns 10,065,187 shares of the biotechnology company’s stock worth $438,540,000 after purchasing an additional 815,497 shares during the last quarter. RA Capital Management L.P. raised its stake in shares of Avidity Biosciences by 18.9% during the third quarter. RA Capital Management L.P. now owns 8,641,031 shares of the biotechnology company’s stock valued at $376,490,000 after purchasing an additional 1,375,000 shares in the last quarter. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Avidity Biosciences by 8.4% in the third quarter. Avoro Capital Advisors LLC now owns 7,645,000 shares of the biotechnology company’s stock valued at $333,093,000 after buying an additional 595,000 shares during the period.

Avidity Biosciences Company Profile

(Get Free Report)